BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012;84:879-880. [PMID: 23078897 DOI: 10.1016/j.ijrobp.2012.06.020] [Cited by in Crossref: 185] [Cited by in F6Publishing: 198] [Article Influence: 18.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen MF, Chen PT, Hsieh CC, Wang CC. Effect of Proton Therapy on Tumor Cell Killing and Immune Microenvironment for Hepatocellular Carcinoma. Cells 2023;12. [PMID: 36672266 DOI: 10.3390/cells12020332] [Reference Citation Analysis]
2 Li J, Lu W, Yang Y, Xiang R, Ling Y, Yu C, Zhou Y. Hybrid Nanomaterials for Cancer Immunotherapy. Adv Sci (Weinh) 2022;:e2204932. [PMID: 36567305 DOI: 10.1002/advs.202204932] [Reference Citation Analysis]
3 Wang J, Sud S, Qu Y, Li L, Zhang J, Marron D, Knape NM, Kim IJ, Wagner KT, Zhang T, Zhao Y, Guo G, Wang AZ. Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model. Neoplasia 2023;36:100864. [PMID: 36571944 DOI: 10.1016/j.neo.2022.100864] [Reference Citation Analysis]
4 Laurent PA, Morel D, Meziani L, Depil S, Deutsch E. Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors. Oncoimmunology 2023;12:2158013. [PMID: 36567802 DOI: 10.1080/2162402X.2022.2158013] [Reference Citation Analysis]
5 Barcellini A, Charalampopoulou A, De Cecco L, Fodor A, Rabaiotti E, Candotti G, Secondino S, Facoetti A, Locati LD, Pignata S, Orlandi E, Mangili G. Ovarian Cancer Radiosensitivity: What Have We Understood So Far? Life (Basel) 2022;13. [PMID: 36675955 DOI: 10.3390/life13010006] [Reference Citation Analysis]
6 Miljanic M, Montalvo S, Aliru M, Song T, Leon-Camarena M, Innella K, Vujovic D, Komaki R, Iyengar P. The Evolving Interplay of SBRT and the Immune System, along with Future Directions in the Field. Cancers (Basel) 2022;14:4530. [PMID: 36139689 DOI: 10.3390/cancers14184530] [Reference Citation Analysis]
7 Zhang Y, Sriramaneni RN, Clark PA, Jagodinsky JC, Ye M, Jin W, Wang Y, Bates A, Kerr CP, Le T, Allawi R, Wang X, Xie R, Havighurst TC, Chakravarty I, Rakhmilevich AL, O'Leary KA, Schuler LA, Sondel PM, Kim K, Gong S, Morris ZS. Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade. Nat Commun 2022;13:4948. [PMID: 35999216 DOI: 10.1038/s41467-022-32645-x] [Reference Citation Analysis]
8 Zhang Y, Xu Z, Chen H, Sun X, Zhang Z. Survival comparison between postoperative and preoperative radiotherapy for stage I-III non-inflammatory breast cancer. Sci Rep 2022;12:14288. [PMID: 35995985 DOI: 10.1038/s41598-022-18251-3] [Reference Citation Analysis]
9 Lin J, Guo Q, Guo Z, Lu T, Chen G, Lin S, Chen M, Chen C, Lu J, Zong J, Tang L, Chen Y, Pan J. Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma. Radiat Oncol 2022;17:117. [PMID: 35790987 DOI: 10.1186/s13014-022-02073-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pompos A, Foote RL, Koong AC, Le QT, Mohan R, Paganetti H, Choy H. National Effort to Re-Establish Heavy Ion Cancer Therapy in the United States. Front Oncol 2022;12:880712. [DOI: 10.3389/fonc.2022.880712] [Reference Citation Analysis]
11 Fossati P, Tubin S, Hug E. The Radiobiology of Particle Therapy. Principles and Practice of Particle Therapy 2022. [DOI: 10.1002/9781119707530.ch3] [Reference Citation Analysis]
12 Shaaban SG, Ebner D, Mohamad O. Particle Therapy and the Immune System. Principles and Practice of Particle Therapy 2022. [DOI: 10.1002/9781119707530.ch11] [Reference Citation Analysis]
13 Zhang R, Kang J, Ren S, Xing L, Xu Y. Comparison of stereotactic body radiotherapy and radiofrequency ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis. Ann Transl Med 2022;10:104. [PMID: 35282118 DOI: 10.21037/atm-21-6256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ocak B, Sarihan S, Şahin AB, Dakiki B, Caner B, Gülşen K, Tanriverdi Ö, Deligönül A, Çubukçu E, Evrensel T. Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer. Turkish Journal of Internal Medicine. [DOI: 10.46310/tjim.1076459] [Reference Citation Analysis]
15 Higgins MJ, Alipour R, Pope K, Ung KA, Kok DL, Chua MS. QUAD SHOT radiotherapy and doublet immunotherapy in the management of anal mucosal melanoma: A case series of efficacy and toxicity of a novel treatment approach and a review of the literature. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.03.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 He D, Ma Z, Xue K, Li H. Juxtamembrane 2 mimic peptide competitively inhibits mitochondrial trafficking and activates ROS-mediated apoptosis pathway to exert anti-tumor effects. Cell Death Dis 2022;13:264. [DOI: 10.1038/s41419-022-04639-6] [Reference Citation Analysis]
17 Gan Y, Li G, Ou X, Wang C, Du Q. Case Report: Chemotherapy and Radiotherapy Combined With DC-CIK for Pulmonary and Mediastinal Metastases From Nasopharyngeal Carcinoma. Front Oncol 2022;12:778643. [DOI: 10.3389/fonc.2022.778643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Venkatesulu BP, Chan DP, Giridhar P, Upadhyay R, Sharma A, Elghazawy H, Elumalai T, V P, Mallick S, Hsieh CE. A systematic review and meta-analysis of the impact of radiation-related lymphopenia on outcomes in pancreatic cancer. Future Oncol 2022. [PMID: 35132868 DOI: 10.2217/fon-2021-0483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Lee YJ, Park YS, Lee HW, Park TY, Lee JK, Heo EY. Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer. Sci Rep 2022;12:626. [PMID: 35022510 DOI: 10.1038/s41598-021-04630-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Borzillo V, Muto P. Radiotherapy in the Treatment of Subcutaneous Melanoma. Cancers (Basel) 2021;13:5859. [PMID: 34831017 DOI: 10.3390/cancers13225859] [Reference Citation Analysis]
21 Gkika E, Adebahr S, Brenner A, Schimek-Jasch T, Radicioni G, Exner JP, Rühle A, Spohn SKB, Popp I, Zamboglou C, Sprave T, Firat E, Niedermann G, Nicolay NH, Nestle U, Grosu AL, Duda DG. Changes in Blood Biomarkers of Angiogenesis and Immune Modulation after Radiation Therapy and Their Association with Outcomes in Thoracic Malignancies. Cancers (Basel) 2021;13:5725. [PMID: 34830880 DOI: 10.3390/cancers13225725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Brix N, Dunn L, Seiwert T, Belka C, Lauber K. Immuntherapie bei Kopf-Hals-Plattenepithelkarzinomen. best practice onkologie 2021;16:520-527. [DOI: 10.1007/s11654-021-00347-3] [Reference Citation Analysis]
23 Zahid MU, Mohsin N, Mohamed ASR, Caudell JJ, Harrison LB, Fuller CD, Moros EG, Enderling H. Forecasting Individual Patient Response to Radiation Therapy in Head and Neck Cancer With a Dynamic Carrying Capacity Model. Int J Radiat Oncol Biol Phys 2021;111:693-704. [PMID: 34102299 DOI: 10.1016/j.ijrobp.2021.05.132] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
24 Link B, Torres Crigna A, Hölzel M, Giordano FA, Golubnitschaja O. Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes? J Clin Med 2021;10:5124. [PMID: 34768644 DOI: 10.3390/jcm10215124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
25 Yasmin-Karim S, Ziberi B, Wirtz J, Bih N, Moreau M, Guthier R, Ainsworth V, Hesser J, Makrigiorgos GM, Chuong MD, Wei X, Nguyen PL, Ngwa W. Boosting the Abscopal Effect Using Immunogenic Biomaterials With Varying Radiation Therapy Field Sizes. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02793-0. [PMID: 34530092 DOI: 10.1016/j.ijrobp.2021.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 He K, Barsoumian HB, Sezen D, Puebla-Osorio N, Hsu EY, Verma V, Abana CO, Chen D, Patel RR, Gu M, Cortez MA, Welsh JW. Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. Front Oncol 2021;11:737425. [PMID: 34497773 DOI: 10.3389/fonc.2021.737425] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Srivastava RM, Purohit TA, Chan TA. Diverse Neoantigens and the Development of Cancer Therapies. Semin Radiat Oncol 2020;30:113-28. [PMID: 32381291 DOI: 10.1016/j.semradonc.2019.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
28 Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, Sriramaneni RN, Jin WJ, Massey C, Rakhmilevich AL, Vail D, Engle JW, Le T, Kim K, Bednarz B, Sondel PM, Weichert J, Morris ZS. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med 2021;13:eabb3631. [PMID: 34261797 DOI: 10.1126/scitranslmed.abb3631] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
29 Li G, Sun B, Li Y, Luo C, He Z, Sun J. Small-Molecule Prodrug Nanoassemblies: An Emerging Nanoplatform for Anticancer Drug Delivery. Small 2021;:e2101460. [PMID: 34342126 DOI: 10.1002/smll.202101460] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
30 Weinfurtner RJ, Raghunand N, Stringfield O, Abdalah M, Niell BL, Ataya D, Williams A, Mooney B, Rosa M, Lee MC, Khakpour N, Laronga C, Czerniecki B, Diaz R, Ahmed K, Washington I, Montejo M. MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. Clin Breast Cancer 2021:S1526-8209(21)00177-4. [PMID: 34384695 DOI: 10.1016/j.clbc.2021.06.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Wu JS, Jen CW, Chen HH, Cheng SH. Stereotactic body radiotherapy and checkpoint inhibitor for locally recurrent unresectable nasopharyngeal carcinoma. BMJ Case Rep 2021;14:e240806. [PMID: 34253513 DOI: 10.1136/bcr-2020-240806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Hu Y, Paris S, Barsoumian H, Abana CO, He K, Wasley M, Younes AI, Masrorpour F, Chen D, Yang L, Dunn JD, Zhang J, Gandhi S, Nguyen QN, Cortez MA, Welsh J. Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)00860-9. [PMID: 34242713 DOI: 10.1016/j.ijrobp.2021.06.041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
33 Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol 2021;162:60-7. [PMID: 34237343 DOI: 10.1016/j.radonc.2021.06.037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
34 Morris Z, Dohopolski M, Rahimi A, Timmerman R. Future Directions in the Use of SAbR for the Treatment of Oligometastatic Cancers. Semin Radiat Oncol 2021;31:253-62. [PMID: 34090653 DOI: 10.1016/j.semradonc.2021.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Mao C, Gorbet MJ, Singh A, Ranjan A, Fiering S. In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology. Int J Hyperthermia 2020;37:4-17. [PMID: 33455477 DOI: 10.1080/02656736.2020.1810333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
36 Janssen QP, van Dam JL, Kivits IG, Besselink MG, van Eijck CHJ, Homs MYV, Nuyttens JJME, Qi H, van Santvoort HJ, Wei AC, de Wilde RF, Wilmink JW, van Tienhoven G, Groot Koerkamp B. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2021. [PMID: 34142290 DOI: 10.1245/s10434-021-10276-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
37 Marciscano AE, Haimovitz-friedman A, Lee P, Tran PT, Tomé WA, Guha C, (Spring) Kong F, Sahgal A, El Naqa I, Rimner A, Marks LB, Formenti SC, Deweese TL. Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. International Journal of Radiation Oncology*Biology*Physics 2021;110:35-52. [DOI: 10.1016/j.ijrobp.2019.02.046] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 16.5] [Reference Citation Analysis]
38 Sita TL, Iyengar P, Abazeed ME, Kruser TJ. Radiotherapy for Metastatic Non–Small Cell Lung Cancer. Advances in Oncology 2021;1:15-28. [DOI: 10.1016/j.yao.2021.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Wang P, Chen Y, Wang C. Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy. Front Oncol 2021;11:672677. [PMID: 33996601 DOI: 10.3389/fonc.2021.672677] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
40 Azoulay M, Chang SD, Gibbs IC, Hancock SL, Pollom EL, Harsh GR, Adler JR, Harraher C, Li G, Hayden Gephart M, Nagpal S, Thomas RP, Recht LD, Jacobs LR, Modlin LA, Wynne J, Seiger K, Fujimoto D, Usoz M, von Eyben R, Choi CYH, Soltys SG. A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes. Neuro Oncol 2020;22:1182-9. [PMID: 32002547 DOI: 10.1093/neuonc/noaa019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
41 Jean-Baptiste SR, Feigenberg SJ, Dorsey JF, Kao GD. Personal and Prognostic: Tissue and Liquid Biomarkers of Radiotherapeutic Response in Non-Small Cell Lung Cancer. Semin Radiat Oncol 2021;31:149-54. [PMID: 33610272 DOI: 10.1016/j.semradonc.2020.11.002] [Reference Citation Analysis]
42 Kong Y, Ma Y, Zhao X, Pan J, Xu Z, Zhang L. Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers. Front Oncol 2021;11:638873. [PMID: 33859942 DOI: 10.3389/fonc.2021.638873] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
43 Kong X, Lu P, Liu C, Guo Y, Yang Y, Peng Y, Wang F, Bo Z, Dou X, Shi H, Meng J. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review). Mol Med Rep 2021;23:362. [PMID: 33760188 DOI: 10.3892/mmr.2021.12001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
44 Brunner TB, Bettinger D, Schultheiss M, Maruschke L, Sturm L, Bartl N, Koundurdjieva I, Kirste S, Neeff HP, Goetz C, Nicolay NH, Ihorst G, Bamberg F, Thimme R, Grosu AL, Gkika E. Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study). Front Oncol 2021;11:653141. [PMID: 33816309 DOI: 10.3389/fonc.2021.653141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Friedrich T, Henthorn N, Durante M. Modeling Radioimmune Response-Current Status and Perspectives. Front Oncol 2021;11:647272. [PMID: 33796470 DOI: 10.3389/fonc.2021.647272] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
46 Gkika E, Hawkins MA, Grosu AL, Brunner TB. The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer. Front Oncol 2020;10:604387. [PMID: 33381458 DOI: 10.3389/fonc.2020.604387] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
47 Wisdom AJ, Mowery YM, Hong CS, Himes JE, Nabet BY, Qin X, Zhang D, Chen L, Fradin H, Patel R, Bassil AM, Muise ES, King DA, Xu ES, Carpenter DJ, Kent CL, Smythe KS, Williams NT, Luo L, Ma Y, Alizadeh AA, Owzar K, Diehn M, Bradley T, Kirsch DG. Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. Nat Commun 2020;11:6410. [PMID: 33335088 DOI: 10.1038/s41467-020-19917-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
48 Hartmann L, Schröter P, Osen W, Baumann D, Offringa R, Moustafa M, Will R, Debus J, Brons S, Rieken S, Eichmüller SB. Photon versus carbon ion irradiation: immunomodulatory effects exerted on murine tumor cell lines. Sci Rep 2020;10:21517. [PMID: 33299018 DOI: 10.1038/s41598-020-78577-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
49 Aluisio G, Mazzeo E, Lohr F, Fiocchi F, Bettelli S, Baldessari C, Paterlini M, Bruni A. Unexpected tumor response to palliative pelvic radiotherapy in mismatch repair-deficient advanced prostate cancer: a case report. J Med Case Rep 2020;14:239. [PMID: 33287897 DOI: 10.1186/s13256-020-02578-4] [Reference Citation Analysis]
50 Deipolyi AR, Johnson CB, Erinjeri JP, Bryce YC. Combination Therapies with Y90: Immunoradiation. Digestive Disease Interventions 2020;04:382-8. [DOI: 10.1055/s-0040-1721454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Pearson JRD, Cuzzubbo S, McArthur S, Durrant LG, Adhikaree J, Tinsley CJ, Pockley AG, McArdle SEB. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment. Front Immunol 2020;11:582106. [PMID: 33178210 DOI: 10.3389/fimmu.2020.582106] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
52 Van Hulle H, Vakaet V, Post G, Van Greveling A, Monten C, Hendrix A, Van de Vijver K, Van Dorpe J, De Visschere P, Braems G, Vandecasteele K, Denys H, De Neve W, Veldeman L. Feasibility study on pre or postoperative accelerated radiotherapy (POP-ART) in breast cancer patients. Pilot Feasibility Stud 2020;6:154. [PMID: 33062295 DOI: 10.1186/s40814-020-00693-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
53 Lurje I, Hammerich L, Tacke F. Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. Int J Mol Sci 2020;21:E7378. [PMID: 33036244 DOI: 10.3390/ijms21197378] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
54 Zhou F, Wang M, Luo T, Qu J, Chen WR. Photo-activated chemo-immunotherapy for metastatic cancer using a synergistic graphene nanosystem. Biomaterials 2021;265:120421. [PMID: 32992117 DOI: 10.1016/j.biomaterials.2020.120421] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 14.3] [Reference Citation Analysis]
55 Ernst A, Hennel R, Krombach J, Kapfhammer H, Brix N, Zuchtriegel G, Uhl B, Reichel CA, Frey B, Gaipl US, Winssinger N, Shirasawa S, Sasazuki T, Sperandio M, Belka C, Lauber K. Priming of Anti-tumor Immune Mechanisms by Radiotherapy Is Augmented by Inhibition of Heat Shock Protein 90. Front Oncol 2020;10:1668. [PMID: 32984042 DOI: 10.3389/fonc.2020.01668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
56 Trommer M, Kinsky J, Adams A, Hellmich M, Schlaak M, von Bergwelt-Baildon M, Celik E, Rosenbrock J, Morgenthaler J, Herter JM, Linde P, Mauch C, Theurich S, Marnitz S, Baues C. Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching. Cancers (Basel) 2020;12:E2429. [PMID: 32867046 DOI: 10.3390/cancers12092429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
57 Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft LE. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat Rev Drug Discov 2020;19:635-52. [PMID: 32764681 DOI: 10.1038/s41573-020-0074-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 20.7] [Reference Citation Analysis]
58 Kalanxhi E, Meltzer S, Ree AH. Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer. Cancers 2020;12:2193. [DOI: 10.3390/cancers12082193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Chen Y, Gao M, Huang Z, Yu J, Meng X. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J Hematol Oncol 2020;13:105. [PMID: 32723363 DOI: 10.1186/s13045-020-00940-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
60 Huang J, Li JJ. Multiple Dynamics in Tumor Microenvironment Under Radiotherapy. Adv Exp Med Biol 2020;1263:175-202. [PMID: 32588328 DOI: 10.1007/978-3-030-44518-8_10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
61 Zhong XF, Sun X. Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy. Acta Pharmacol Sin 2020;41:928-35. [PMID: 32355277 DOI: 10.1038/s41401-020-0414-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
62 Jarosz-Biej M, Smolarczyk R, Cichoń T, Drzyzga A, Czapla J, Urbaś Z, Pilny E, Matuszczak S, Wojcieszek P. Brachytherapy in a Single Dose of 10Gy as an "in situ" Vaccination. Int J Mol Sci 2020;21:E4585. [PMID: 32605154 DOI: 10.3390/ijms21134585] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
63 Salomon N, Vascotto F, Selmi A, Vormehr M, Quinkhardt J, Bukur T, Schrörs B, Löewer M, Diken M, Türeci Ö, Sahin U, Kreiter S. A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice. Oncoimmunology 2020;9:1771925. [PMID: 32923128 DOI: 10.1080/2162402X.2020.1771925] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
64 López Alfonso JC, Poleszczuk J, Walker R, Kim S, Pilon-Thomas S, Conejo-Garcia JJ, Soliman H, Czerniecki B, Harrison LB, Enderling H. Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. JCO Clin Cancer Inform 2019;3:1-16. [PMID: 30964698 DOI: 10.1200/CCI.18.00075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
65 Brix N, Dunn L, Seiwert T, Belka C, Lauber K. [Immunotherapy in head and neck squamous cell carcinoma : Abscopal effects in combination with radiotherapy, extraordinary responses in combination with chemotherapy, and pseudoprogression]. Internist (Berl) 2020;61:682-9. [PMID: 32462252 DOI: 10.1007/s00108-020-00816-x] [Reference Citation Analysis]
66 Bouzid R, Peppelenbosch M, Buschow SI. Opportunities for Conventional and in Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. Cancers (Basel) 2020;12:E1121. [PMID: 32365838 DOI: 10.3390/cancers12051121] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
67 Lin W, Xu Y, Chen X, Liu J, Weng Y, Zhuang Q, Lin F, Huang Z, Wu S, Ding J, Chen L, Qiu X, Zhang L, Wu J, Lin D, Qiu S. Radiation-induced small extracellular vesicles as "carriages" promote tumor antigen release and trigger antitumor immunity. Theranostics 2020;10:4871-84. [PMID: 32308755 DOI: 10.7150/thno.43539] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
68 Samaranayake CB, McCaffrey E, Coucher J, Lehman M, Mai GT, Murphy MA. Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study. ERJ Open Res 2020;6:00189-2019. [PMID: 32166087 DOI: 10.1183/23120541.00189-2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Wisdom AJ, Mowery YM, Hong CS, Qin X, Zhang D, Himes JE, Chen L, Fradin H, Muise ES, Xu ES, Carpenter DJ, Kent CL, Smythe KS, Williams N, Luo L, Ma Y, Owzar K, Bradley T, Kirsch DG. A single cell atlas reveals distinct immune landscapes in transplant and primary tumors that determine response or resistance to immunotherapy.. [DOI: 10.1101/2020.03.11.978387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
70 Demaria S, Formenti SC. The abscopal effect 67 years later: from a side story to center stage. Br J Radiol 2020;93:20200042. [PMID: 32101479 DOI: 10.1259/bjr.20200042] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 14.7] [Reference Citation Analysis]
71 Wrona A. Role of immunotherapy in stage III nonsmall cell lung cancer. Curr Opin Oncol 2019;31:18-23. [PMID: 30489337 DOI: 10.1097/CCO.0000000000000493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
72 Tian S, Switchenko JM, Buchwald ZS, Patel PR, Shelton JW, Kahn SE, Pillai RN, Steuer CE, Owonikoko TK, Behera M, Curran WJ, Higgins KA. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. Int J Radiat Oncol Biol Phys. 2020;108:304-313. [PMID: 31982496 DOI: 10.1016/j.ijrobp.2019.12.030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
73 Farias VA, Tovar I, Del Moral R, O'Valle F, Expósito J, Oliver FJ, Ruiz de Almodóvar JM. Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes. Front Oncol 2019;9:1381. [PMID: 31970082 DOI: 10.3389/fonc.2019.01381] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
74 Sun X, Gan L, Na A, Ge L, Chen B, Liu J. Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer. J Oncol 2019;2019:1483406. [PMID: 31871454 DOI: 10.1155/2019/1483406] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
75 Huyghe N, Baldin P, Van den Eynde M. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? Gastroenterol Rep (Oxf) 2020;8:11-24. [PMID: 32104582 DOI: 10.1093/gastro/goz061] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
76 Lee VH, Yang L, Jiang Y, Kong FS. Radiation Therapy for Thoracic Malignancies. Hematol Oncol Clin North Am 2020;34:109-25. [PMID: 31739938 DOI: 10.1016/j.hoc.2019.09.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
77 Suker M, Nuyttens JJ, Eskens FALM, Haberkorn BCM, Coene PLO, van der Harst E, Bonsing BA, Vahrmeijer AL, Mieog JSD, Jan Swijnenburg R, Roos D, Koerkamp BG, van Eijck CHJ. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). EClinicalMedicine 2019;17:100200. [PMID: 31891135 DOI: 10.1016/j.eclinm.2019.10.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
78 Li Y, Ayala-Orozco C, Rauta PR, Krishnan S. The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective. Nanoscale 2019;11:17157-78. [PMID: 31531445 DOI: 10.1039/c9nr05371a] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
79 Dutt S, Atallah MB, Minamida Y, Filatenkov A, Jensen KP, Iliopoulou BP, Tamosiuniene R, Waters J, Engleman EG, Strober S. Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions. Blood Adv 2018;2:2568-80. [PMID: 30301812 DOI: 10.1182/bloodadvances.2018023119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
80 Gjyshi O, Liao Z. Proton therapy for locally advanced non-small cell lung cancer. Br J Radiol 2020;93:20190378. [PMID: 31430188 DOI: 10.1259/bjr.20190378] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
81 Lhuillier C, Rudqvist NP, Elemento O, Formenti SC, Demaria S. Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Med 2019;11:40. [PMID: 31221199 DOI: 10.1186/s13073-019-0653-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 115] [Article Influence: 27.0] [Reference Citation Analysis]
82 Rockne RC, Hawkins-Daarud A, Swanson KR, Sluka JP, Glazier JA, Macklin P, Hormuth DA, Jarrett AM, Lima EABF, Tinsley Oden J, Biros G, Yankeelov TE, Curtius K, Al Bakir I, Wodarz D, Komarova N, Aparicio L, Bordyuh M, Rabadan R, Finley SD, Enderling H, Caudell J, Moros EG, Anderson ARA, Gatenby RA, Kaznatcheev A, Jeavons P, Krishnan N, Pelesko J, Wadhwa RR, Yoon N, Nichol D, Marusyk A, Hinczewski M, Scott JG. The 2019 mathematical oncology roadmap. Phys Biol 2019;16:041005. [PMID: 30991381 DOI: 10.1088/1478-3975/ab1a09] [Cited by in Crossref: 103] [Cited by in F6Publishing: 109] [Article Influence: 25.8] [Reference Citation Analysis]
83 Falcón-Beas C, Tittarelli A, Mora-Bau G, Tempio F, Pérez C, Hevia D, Behrens C, Flores I, Falcón-Beas F, Garrido P, Ascui G, Pereda C, González FE, Salazar-Onfray F, López MN. Dexamethasone turns tumor antigen-presenting cells into tolerogenic dendritic cells with T cell inhibitory functions. Immunobiology 2019;224:697-705. [PMID: 31221438 DOI: 10.1016/j.imbio.2019.05.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
84 Vapiwala N, Thomas CR Jr, Grover S, Yap ML, Mitin T, Shulman LN, Gospodarowicz MK, Longo J, Petereit DG, Ennis RD, Hayman JA, Rodin D, Buchsbaum JC, Vikram B, Abdel-Wahab M, Epstein AH, Okunieff P, Goldwein J, Kupelian P, Weidhaas JB, Tucker MA, Boice JD Jr, Fuller CD, Thompson RF, Trister AD, Formenti SC, Barcellos-Hoff MH, Jones J, Dharmarajan KV, Zietman AL, Coleman CN. Enhancing Career Paths for Tomorrow's Radiation Oncologists. Int J Radiat Oncol Biol Phys 2019;105:52-63. [PMID: 31128144 DOI: 10.1016/j.ijrobp.2019.05.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
85 Trommer M, Yeo SY, Persigehl T, Bunck A, Grüll H, Schlaak M, Theurich S, von Bergwelt-Baildon M, Morgenthaler J, Herter JM, Celik E, Marnitz S, Baues C. Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition. Front Pharmacol 2019;10:511. [PMID: 31156434 DOI: 10.3389/fphar.2019.00511] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
86 Lauber K, Dunn L. Immunotherapy Mythbusters in Head and Neck Cancer: The Abscopal Effect and Pseudoprogression. American Society of Clinical Oncology Educational Book 2019. [DOI: 10.1200/edbk_238339] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
87 Nam J, Son S, Park KS, Zou W, Shea LD, Moon JJ. Cancer nanomedicine for combination cancer immunotherapy. Nat Rev Mater 2019;4:398-414. [DOI: 10.1038/s41578-019-0108-1] [Cited by in Crossref: 416] [Cited by in F6Publishing: 426] [Article Influence: 104.0] [Reference Citation Analysis]
88 Spring BQ, Lang RT, Kercher EM, Rizvi I, Wenham RM, Conejo-Garcia JR, Hasan T, Gatenby RA, Enderling H. Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies. Front Phys 2019;7:46. [PMID: 31123672 DOI: 10.3389/fphy.2019.00046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
89 Yang H, Jin T, Li M, Xue J, Lu B. Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges. Precision Clinical Medicine 2019;2:57-70. [DOI: 10.1093/pcmedi/pbz004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
90 Appenheimer MM, Evans SS. Temperature and adaptive immunity. Handb Clin Neurol 2018;156:397-415. [PMID: 30454603 DOI: 10.1016/B978-0-444-63912-7.00024-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
91 Wang Y, Zenkoh J, Gerelchuluun A, Sun L, Cai S, Li X, Tsuboi K. Administration of Dendritic Cells and Anti-PD-1 Antibody Converts X-ray Irradiated Tumors Into Effective In situ Vaccines. International Journal of Radiation Oncology*Biology*Physics 2019;103:958-69. [DOI: 10.1016/j.ijrobp.2018.11.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
92 Janko C, Ratschker T, Nguyen K, Zschiesche L, Tietze R, Lyer S, Alexiou C. Functionalized Superparamagnetic Iron Oxide Nanoparticles (SPIONs) as Platform for the Targeted Multimodal Tumor Therapy. Front Oncol 2019;9:59. [PMID: 30815389 DOI: 10.3389/fonc.2019.00059] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
93 Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen KJ, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer 2019;7:38. [PMID: 30736848 DOI: 10.1186/s40425-019-0520-5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 17.3] [Reference Citation Analysis]
94 Wang K, Li HL, Xiong YF, Shi Y, Li ZY, Li J, Zhang X, Li HY. Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study. Cancer Med 2019;8:686-700. [PMID: 30677255 DOI: 10.1002/cam4.1880] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
95 Billena C, Khan AJ. A Current Review of Spatial Fractionation: Back to the Future? Int J Radiat Oncol Biol Phys 2019;104:177-87. [PMID: 30684666 DOI: 10.1016/j.ijrobp.2019.01.073] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 13.5] [Reference Citation Analysis]
96 Fan TM, Selting KA. Exploring the Potential Utility of Pet Dogs With Cancer for Studying Radiation-Induced Immunogenic Cell Death Strategies. Front Oncol 2018;8:680. [PMID: 30697532 DOI: 10.3389/fonc.2018.00680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
97 Wisdom AJ, Mowery YM, Kirsch DG. Radiation and Immunotherapy for Sarcoma. Immunotherapy of Sarcoma 2019. [DOI: 10.1007/978-3-319-93530-0_4] [Reference Citation Analysis]
98 Liu H, Wang H, Wu J, Wang Y, Zhao L, Li G, Zhou M. Lymphocyte nadir predicts tumor response and survival in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: Immunologic relevance. Radiother Oncol 2019;131:52-9. [PMID: 30773187 DOI: 10.1016/j.radonc.2018.12.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
99 Kabarriti R, Baliga S, Ohri N, Guha C, Kalnicki S, Garg MK. Radiation therapy for patients with newly diagnosed metastatic head and neck squamous cell carcinoma. Head & Neck 2018. [DOI: 10.1002/hed.25476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
100 Wang SJ, Haffty B. Radiotherapy as a New Player in Immuno-Oncology. Cancers (Basel). 2018;10. [PMID: 30558196 DOI: 10.3390/cancers10120515] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
101 Tsoutsou PG, Zaman K, Martin Lluesma S, Cagnon L, Kandalaft L, Vozenin MC. Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. Front Oncol 2018;8:609. [PMID: 30619749 DOI: 10.3389/fonc.2018.00609] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
102 Yi M, Qin S, Zhao W, Yu S, Chu Q, Wu K. The role of neoantigen in immune checkpoint blockade therapy. Exp Hematol Oncol 2018;7:28. [PMID: 30473928 DOI: 10.1186/s40164-018-0120-y] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 13.8] [Reference Citation Analysis]
103 Rathke H, Flechsig P, Mier W, Bronzel M, Mavriopoulou E, Hohenfellner M, Giesel FL, Haberkorn U, Kratochwil C. Dosimetry Estimate and Initial Clinical Experience with 90Y-PSMA-617. J Nucl Med 2019;60:806-11. [PMID: 30389816 DOI: 10.2967/jnumed.118.218917] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
104 Bornstein S, Formenti SC. Introduction to the special edition on immunotherapy and radiation oncology. Adv Radiat Oncol 2018;3:484-5. [PMID: 30370346 DOI: 10.1016/j.adro.2018.08.019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Trommer-Nestler M, Marnitz S, Kocher M, Rueß D, Schlaak M, Theurich S, von Bergwelt-Baildon M, Morgenthaler J, Jablonska K, Celik E, Ruge MI, Baues C. Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment. Int J Mol Sci 2018;19:E2653. [PMID: 30205431 DOI: 10.3390/ijms19092653] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
106 Lazzari G, Terlizzi A, Porrazzo G, Devicienti S, Perri F, Della Vittoria Scarpati G, Silvano G. Effective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report. Onco Targets Ther 2018;11:4621-9. [PMID: 30122953 DOI: 10.2147/OTT.S176226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
107 Zhou F, Yang J, Zhang Y, Liu M, Lang ML, Li M, Chen WR. Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine. Clin Cancer Res 2018;24:5335-46. [PMID: 30068705 DOI: 10.1158/1078-0432.CCR-18-1126] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 11.2] [Reference Citation Analysis]
108 Stea B, Skrepnik T, Hsu CC, Abendroth R. The role of radiation therapy in the treatment of metastatic cancer. Clin Exp Metastasis. 2018;35:535-546. [PMID: 30062507 DOI: 10.1007/s10585-018-9926-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
109 Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. Trends Immunol 2018;39:644-55. [PMID: 30001871 DOI: 10.1016/j.it.2018.06.001] [Cited by in Crossref: 200] [Cited by in F6Publishing: 174] [Article Influence: 40.0] [Reference Citation Analysis]
110 Walker R, Poleszczuk J, Pilon-Thomas S, Kim S, Anderson AARA, Czerniecki BJ, Harrison LB, Moros EG, Enderling H. Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy. Sci Rep 2018;8:9474. [PMID: 29930290 DOI: 10.1038/s41598-018-27718-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
111 Ni K, Lan G, Chan C, Quigley B, Lu K, Aung T, Guo N, La Riviere P, Weichselbaum RR, Lin W. Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 2018;9:2351. [PMID: 29907739 DOI: 10.1038/s41467-018-04703-w] [Cited by in Crossref: 176] [Cited by in F6Publishing: 187] [Article Influence: 35.2] [Reference Citation Analysis]
112 Koo KC, Dasgupta P. Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review. Yonsei Med J 2018;59:567-79. [PMID: 29869454 DOI: 10.3349/ymj.2018.59.5.567] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
113 Gong J, Lang BJ, Weng D, Eguchi T, Murshid A, Borges TJ, Doshi S, Song B, Stevenson MA, Calderwood SK. Genotoxic stress induces Sca-1-expressing metastatic mammary cancer cells. Mol Oncol 2018;12:1249-63. [PMID: 29738110 DOI: 10.1002/1878-0261.12321] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
114 Loblaw A, Liu S, Cheung P. Stereotactic ablative body radiotherapy in patients with prostate cancer. Transl Androl Urol 2018;7:330-40. [PMID: 30050794 DOI: 10.21037/tau.2018.01.18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
115 Moran MS, Truong PT. Radiation, then On to Surgery. Int J Radiat Oncol Biol Phys 2018;101:265. [PMID: 29726354 DOI: 10.1016/j.ijrobp.2018.02.156] [Reference Citation Analysis]
116 Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280:249-279. [PMID: 29027221 DOI: 10.1111/imr.12573] [Cited by in Crossref: 105] [Cited by in F6Publishing: 115] [Article Influence: 21.0] [Reference Citation Analysis]
117 Frey B, Rückert M, Deloch L, Rühle PF, Derer A, Fietkau R, Gaipl US. Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases. Immunol Rev 2017;280:231-48. [PMID: 29027224 DOI: 10.1111/imr.12572] [Cited by in Crossref: 103] [Cited by in F6Publishing: 108] [Article Influence: 20.6] [Reference Citation Analysis]
118 Bhalla N, Brooker R, Brada M. Combining immunotherapy and radiotherapy in lung cancer. J Thorac Dis 2018;10:S1447-60. [PMID: 29951296 DOI: 10.21037/jtd.2018.05.107] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 7.6] [Reference Citation Analysis]
119 McGee HM, Daly ME, Azghadi S, Stewart SL, Oesterich L, Schlom J, Donahue R, Schoenfeld JD, Chen Q, Rao S, Fragoso RC, Valicenti RK, Canter RJ, Maverakis EM, Murphy WJ, Kelly K, Monjazeb AM. Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. Int J Radiat Oncol Biol Phys 2018;101:1259-70. [PMID: 29891204 DOI: 10.1016/j.ijrobp.2018.04.038] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
120 Lazzari C, Karachaliou N, Bulotta A, Viganó M, Mirabile A, Brioschi E, Santarpia M, Gianni L, Rosell R, Gregorc V. Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? Ther Adv Med Oncol 2018;10:1758835918762094. [PMID: 29662546 DOI: 10.1177/1758835918762094] [Cited by in Crossref: 73] [Cited by in F6Publishing: 83] [Article Influence: 14.6] [Reference Citation Analysis]
121 Chmura SJ, Connell PP, Weichselbaum RR. Retuning the Radio in Radiobiology. J Natl Cancer Inst 2018;110:325-6. [PMID: 29126281 DOI: 10.1093/jnci/djx234] [Reference Citation Analysis]
122 Schapira E, Hubbeling H, Yeap BY, Mehan WA Jr, Shaw AT, Oh K, Gainor JF, Shih HA. Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. Int J Radiat Oncol Biol Phys 2018;101:624-9. [PMID: 29678530 DOI: 10.1016/j.ijrobp.2018.02.175] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 14.2] [Reference Citation Analysis]
123 Moreau M, Yasmin-Karim S, Kunjachan S, Sinha N, Gremse F, Kumar R, Chow KF, Ngwa W. Priming the Abscopal Effect Using Multifunctional Smart Radiotherapy Biomaterials Loaded with Immunoadjuvants. Front Oncol 2018;8:56. [PMID: 29594038 DOI: 10.3389/fonc.2018.00056] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
124 Yanagisawa M, Gingrich AA, Judge S, Li CS, Wang N, Thorpe SW, Kirane AR, Bold RJ, Monjazeb AM, Canter RJ. Serum C-reactive Protein and Neutrophil/Lymphocyte Ratio After Neoadjuvant Radiotherapy in Soft Tissue Sarcoma. Anticancer Res 2018;38:1491-7. [PMID: 29491077 DOI: 10.21873/anticanres.12376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
125 Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 2018;36:1611-8. [PMID: 29437535 DOI: 10.1200/JCO.2017.76.2229] [Cited by in Crossref: 301] [Cited by in F6Publishing: 331] [Article Influence: 60.2] [Reference Citation Analysis]
126 Cadena A, Cushman TR, Anderson C, Barsoumian HB, Welsh JW, Cortez MA. Radiation and Anti-Cancer Vaccines: A Winning Combination. Vaccines (Basel) 2018;6:E9. [PMID: 29385680 DOI: 10.3390/vaccines6010009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
127 Marciscano AE, Walker JM, McGee HM, Kim MM, Kunos CA, Monjazeb AM, Shiao SL, Tran PT, Ahmed MM. Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop. J Immunother Cancer 2018;6:6. [PMID: 29375032 DOI: 10.1186/s40425-018-0317-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
128 Kobayashi K, Nakachi I, Naoki K, Satomi R, Nakamura M, Inoue T, Tateno H, Sakamaki F, Sayama K, Terashima T, Koh H, Abe T, Nishino M, Arai D, Yasuda H, Kawada I, Soejima K, Betsuyaku T; Keio Lung Oncology Group (KLOG). Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis. Clin Lung Cancer 2018;19:e349-58. [PMID: 29398578 DOI: 10.1016/j.cllc.2018.01.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
129 Ye JC, Formenti SC. Integration of radiation and immunotherapy in breast cancer - Treatment implications. Breast 2018;38:66-74. [PMID: 29253718 DOI: 10.1016/j.breast.2017.12.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
130 Tchelebi L, Zaorsky N, Mackley H. Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. Biomedicines 2018;6:E7. [PMID: 29301352 DOI: 10.3390/biomedicines6010007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
131 Demaria S, Bornstein S, Formenti SC. Synergy Between Radiotherapy and Immunotherapy. Oncoimmunology 2018. [DOI: 10.1007/978-3-319-62431-0_30] [Reference Citation Analysis]
132 El Naqa I, Milano MT, Ohri N, Moiseenko V, Moros EG, Deasy JO, Grimm J, Xue J, Martel M, Ten Haken RK. Big Data Approaches to Improve Stereotactic Body Radiation Therapy (SBRT) Outcomes. Emerging Developments and Practices in Oncology 2018. [DOI: 10.4018/978-1-5225-3085-5.ch004] [Reference Citation Analysis]
133 Mohan R, Held KD, Story MD, Grosshans D, Capala J. Proceedings of the National Cancer Institute Workshop on Charged Particle Radiobiology. Int J Radiat Oncol Biol Phys 2018;100:816-31. [PMID: 29485053 DOI: 10.1016/j.ijrobp.2017.12.260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
134 Gholami YH, Wilson N, James D, Kuncic Z. Toward Personalized Dosimetry with 32 P Microparticle Therapy for Advanced Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics 2017;99:1029-38. [DOI: 10.1016/j.ijrobp.2017.07.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
135 Baumann R, Dunst J. Radiotherapie verstärkt Wirkung von PD-1-Checkpointinhibitoren. Info Onkol 2017;20:19-20. [DOI: 10.1007/s15004-017-5807-4] [Reference Citation Analysis]
136 Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, Tassone P, Tagliaferri P, Pirtoli L, Correale P. Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). Oncotarget 2017;8:75904-13. [PMID: 29100279 DOI: 10.18632/oncotarget.20411] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
137 Moding EJ, Mowery YM, Kirsch DG. Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era. Cancer J 2016;22:267-73. [PMID: 27441746 DOI: 10.1097/PPO.0000000000000203] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
138 Rodriguez-Ruiz ME, Rodriguez I, Barbes B, Mayorga L, Sanchez-Paulete AR, Ponz-Sarvise M, Pérez-Gracia JL, Melero I. Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. Brachytherapy 2017;16:1246-51. [PMID: 28838649 DOI: 10.1016/j.brachy.2017.06.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
139 Zhang J, Kong L, Jiao Q, Li M, Yu J. Stereotactic ablative radiotherapy in treatment of early-stage non-small cell lung cancer: Unsolved questions and frontiers ahead. Cancer Lett 2017;401:46-52. [PMID: 28526616 DOI: 10.1016/j.canlet.2017.04.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
140 Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5395-5404 [PMID: 28839440 DOI: 10.3748/wjg.v23.i29.5395] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
141 Baues C, Schlaak M, von Bergwelt-baildon M, Theurich S. Should we be combining local tumor therapies with immunotherapies as standard? Future Oncology 2017;13:1573-5. [DOI: 10.2217/fon-2017-0150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
142 Baumann R, Dunst J. Radiotherapie verstärkt Wirkung von PD-1-Checkpoint-Inhibitoren. Strahlenther Onkol 2017;193:763-4. [DOI: 10.1007/s00066-017-1179-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
143 Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res 2017;19:75. [PMID: 28666457 DOI: 10.1186/s13058-017-0870-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
144 Xie G, Gu D, Zhang L, Chen S, Wu D. A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma. Cancer Biol Ther 2017;18:547-51. [PMID: 28665741 DOI: 10.1080/15384047.2017.1345389] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
145 Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18:895-903. [PMID: 28551359 DOI: 10.1016/s1470-2045(17)30380-7] [Cited by in Crossref: 588] [Cited by in F6Publishing: 670] [Article Influence: 98.0] [Reference Citation Analysis]
146 Baues C, Trommer-Nestler M, Jablonska K, Bröckelmann PJ, Schlaak M, von Bergwelt-Baildon M, Engert A, Semrau R, Marnitz S, Theurich S. Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. Immunotherapy 2017;9:423-33. [PMID: 28357914 DOI: 10.2217/imt-2017-0002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
147 Kodra J, Miles D, Yoon SW, Kirsch DG, Oldham M. Characterization of novel preclinical dose distributions for micro irradiator. J Phys : Conf Ser 2017;847:012054. [DOI: 10.1088/1742-6596/847/1/012054] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
148 Ngwa W, Ouyang Z. Following the Preclinical Data: Leveraging the Abscopal Effect More Efficaciously. Front Oncol 2017;7:66. [PMID: 28447024 DOI: 10.3389/fonc.2017.00066] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
149 Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, García-Martínez E, Rudqvist NP, Formenti SC, Demaria S. Barriers to Radiation-Induced In Situ Tumor Vaccination. Front Immunol 2017;8:229. [PMID: 28348554 DOI: 10.3389/fimmu.2017.00229] [Cited by in Crossref: 117] [Cited by in F6Publishing: 124] [Article Influence: 19.5] [Reference Citation Analysis]
150 Ebner DK, Tinganelli W, Helm A, Bisio A, Yamada S, Kamada T, Shimokawa T, Durante M. The Immunoregulatory Potential of Particle Radiation in Cancer Therapy. Front Immunol 2017;8:99. [PMID: 28220126 DOI: 10.3389/fimmu.2017.00099] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
151 Weichselbaum RR, Liang H, Deng L, Fu Y. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 2017;14:365-79. [DOI: 10.1038/nrclinonc.2016.211] [Cited by in Crossref: 540] [Cited by in F6Publishing: 564] [Article Influence: 90.0] [Reference Citation Analysis]
152 Wong JYC, Hui S, Dandapani SV, Liu A. Biologic and Image Guided Systemic Radiotherapy. Cancer Treatment and Research 2017. [DOI: 10.1007/978-3-319-53235-6_8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
153 Balogun O, Formenti SC. Combining Radiotherapy and Immunotherapy. Cancer Treatment and Research 2017. [DOI: 10.1007/978-3-319-53235-6_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
154 Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res. 2016;22:1845-1855. [PMID: 27084738 DOI: 10.1158/1078-0432.ccr-16-0049] [Cited by in Crossref: 182] [Cited by in F6Publishing: 193] [Article Influence: 26.0] [Reference Citation Analysis]
155 George DD, Armenio VA, Katz SC. Combinatorial immunotherapy for melanoma. Cancer Gene Ther 2017;24:141-7. [PMID: 27834353 DOI: 10.1038/cgt.2016.56] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
156 Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology 2016;5:e1214790. [PMID: 27757313 DOI: 10.1080/2162402X.2016.1214790] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 7.7] [Reference Citation Analysis]
157 Formenti SC. The Pace of Progress in Radiation and Immunotherapy. International Journal of Radiation Oncology*Biology*Physics 2016;95:1257-8. [DOI: 10.1016/j.ijrobp.2016.02.063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
158 Kroon P, Gadiot J, Peeters M, Gasparini A, Deken MA, Yagita H, Verheij M, Borst J, Blank CU, Verbrugge I. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Cancer Immunol Immunother 2016;65:753-63. [PMID: 27160390 DOI: 10.1007/s00262-016-1843-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
159 Morgan MA, Lawrence TS. Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. Clin Cancer Res 2015;21:2898-904. [PMID: 26133775 DOI: 10.1158/1078-0432.CCR-13-3229] [Cited by in Crossref: 133] [Cited by in F6Publishing: 142] [Article Influence: 19.0] [Reference Citation Analysis]
160 Goyal S, Silk AW, Tian S, Mehnert J, Danish S, Ranjan S, Kaufman HL. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. JAMA Oncol 2015;1:668-76. [PMID: 26181286 DOI: 10.1001/jamaoncol.2015.1206] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 8.3] [Reference Citation Analysis]
161 Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol 2016;13:516-24. [PMID: 26951040 DOI: 10.1038/nrclinonc.2016.30] [Cited by in Crossref: 195] [Cited by in F6Publishing: 220] [Article Influence: 27.9] [Reference Citation Analysis]
162 Schnurr M, Duewell P, Bauer C, Rothenfusser S, Lauber K, Endres S, Kobold S. Strategies to relieve immunosuppression in pancreatic cancer. Immunotherapy 2015;7:363-76. [PMID: 25917628 DOI: 10.2217/imt.15.9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
163 Cooper B, Vatner R, Golden E, Silverman J, Formenti S. The Immune System and Its Contribution to the Radiotherapeutic Response of Glioblastoma. Current Clinical Pathology 2016. [DOI: 10.1007/978-3-319-28305-0_10] [Reference Citation Analysis]
164 Mohiuddin M, Park H, Hallmeyer S, Richards J. High-Dose Radiation as a Dramatic, Immunological Primer in Locally Advanced Melanoma. Cureus 2015;7:e417. [PMID: 26848410 DOI: 10.7759/cureus.417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
165 Huang Y, Chen W, Teh BS, Butler EB. Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials. J Radiat Oncol 2015;4:365-75. [DOI: 10.1007/s13566-015-0240-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
166 Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015;33:3293-304. [PMID: 26351330 DOI: 10.1200/JCO.2015.61.1509] [Cited by in Crossref: 397] [Cited by in F6Publishing: 424] [Article Influence: 49.6] [Reference Citation Analysis]
167 Michels J, Yamasaki T, Apetoh L. Immunogénicité de la chimiothérapie. Oncologie 2015;17:345-353. [DOI: 10.1007/s10269-015-2543-y] [Reference Citation Analysis]
168 Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 2015;33:7415-22. [PMID: 26148880 DOI: 10.1016/j.vaccine.2015.05.105] [Cited by in Crossref: 114] [Cited by in F6Publishing: 119] [Article Influence: 14.3] [Reference Citation Analysis]
169 Schaue D, Mcbride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol 2015;12:527-40. [DOI: 10.1038/nrclinonc.2015.120] [Cited by in Crossref: 251] [Cited by in F6Publishing: 277] [Article Influence: 31.4] [Reference Citation Analysis]
170 Meyer J, Toomay S. Update on treatment of liver metastases: focus on ablation therapies. Curr Oncol Rep. 2015;17:420. [PMID: 25416314 DOI: 10.1007/s11912-014-0420-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
171 Chow KK, Hara W, Lim M, Li G. Combining immunotherapy with radiation for the treatment of glioblastoma. J Neurooncol 2015;123:459-64. [PMID: 25877468 DOI: 10.1007/s11060-015-1762-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
172 Surace L, Lysenko V, Fontana AO, Cecconi V, Janssen H, Bicvic A, Okoniewski M, Pruschy M, Dummer R, Neefjes J, Knuth A, Gupta A, van den Broek M. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. Immunity 2015;42:767-77. [PMID: 25888260 DOI: 10.1016/j.immuni.2015.03.009] [Cited by in Crossref: 105] [Cited by in F6Publishing: 111] [Article Influence: 13.1] [Reference Citation Analysis]
173 Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, Barcellos-Hoff MH, Demaria S. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res 2015;75:2232-42. [PMID: 25858148 DOI: 10.1158/0008-5472.CAN-14-3511] [Cited by in Crossref: 336] [Cited by in F6Publishing: 352] [Article Influence: 42.0] [Reference Citation Analysis]
174 Kepp O, Semeraro M, Bravo-San Pedro JM, Bloy N, Buqué A, Huang X, Zhou H, Senovilla L, Kroemer G, Galluzzi L. eIF2α phosphorylation as a biomarker of immunogenic cell death. Semin Cancer Biol. 2015;33:86-92. [PMID: 25749194 DOI: 10.1016/j.semcancer.2015.02.004] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 9.4] [Reference Citation Analysis]
175 Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology 2015;4:e1008866. [PMID: 26137404 DOI: 10.1080/2162402X.2015.1008866] [Cited by in Crossref: 165] [Cited by in F6Publishing: 157] [Article Influence: 20.6] [Reference Citation Analysis]
176 Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3:e955691. [PMID: 25941621 DOI: 10.4161/21624011.2014.955691] [Cited by in Crossref: 542] [Cited by in F6Publishing: 570] [Article Influence: 60.2] [Reference Citation Analysis]
177 Shin SM, Chouake RJ, Sanfilippo NJ, Rapp TB, Cook P, Formenti SC, Mazumder A, Silverman JS. Feasibility and Efficacy of Local Radiotherapy With Concurrent Novel Agents in Patients With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 2014;14:480-4. [DOI: 10.1016/j.clml.2014.07.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
178 Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol. 2014;4:325. [PMID: 25506582 DOI: 10.3389/fonc.2014.00325] [Cited by in Crossref: 157] [Cited by in F6Publishing: 173] [Article Influence: 17.4] [Reference Citation Analysis]
179 Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S;  International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259-271. [PMID: 25214542 DOI: 10.1093/annonc/mdu450] [Cited by in Crossref: 1473] [Cited by in F6Publishing: 1547] [Article Influence: 163.7] [Reference Citation Analysis]
180 Rekers NH, Troost EG, Zegers CM, Germeraad WT, Dubois LJ, Lambin P. Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives. Cancer Radiother 2014;18:391-5. [PMID: 25179250 DOI: 10.1016/j.canrad.2014.06.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
181 Yao HH, Hong MKh, Corcoran NM, Siva S, Foroudi F. Advances in local and ablative treatment of oligometastasis in prostate cancer. Asia Pac J Clin Oncol 2014;10:308-21. [PMID: 25155557 DOI: 10.1111/ajco.12256] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
182 Mantovani A, Vecchi A, Allavena P. Pharmacological modulation of monocytes and macrophages. Curr Opin Pharmacol 2014;17:38-44. [PMID: 25062123 DOI: 10.1016/j.coph.2014.07.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
183 Kanagavelu S, Gupta S, Wu X, Philip S, Wattenberg MM, Hodge JW, Couto MD, Chung KD, Ahmed MM. In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation. Radiat Res 2014;182:149-62. [PMID: 25036982 DOI: 10.1667/RR3819.1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 6.7] [Reference Citation Analysis]
184 Wattenberg MM, Fahim A, Ahmed MM, Hodge JW. Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res 2014;182:126-38. [PMID: 24960415 DOI: 10.1667/RR13374.1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
185 Lim JY, Brockstedt DG, Lord EM, Gerber SA. Radiation therapy combined with Listeria monocytogenes-based cancer vaccine synergize to enhance tumor control in the B16 melanoma model. Oncoimmunology 2014;3:e29028. [PMID: 25083327 DOI: 10.4161/onci.29028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
186 de la Cruz-Merino L, Illescas-Vacas A, Grueso-López A, Barco-Sánchez A, Míguez-Sánchez C. Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored. Front Immunol. 2014;5:102. [PMID: 24672524 DOI: 10.3389/fimmu.2014.00102/abstract] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
187 de la Cruz-Merino L, Illescas-Vacas A, Grueso-López A, Barco-Sánchez A, Míguez-Sánchez C; Cancer Immunotherapies Spanish Group (GETICA). Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored. Front Immunol 2014;5:102. [PMID: 24672524 DOI: 10.3389/fimmu.2014.00102] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
188 Zeng J, Harris TJ, Lim M, Drake CG, Tran PT. Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res Int 2013;2013:658126. [PMID: 24324970 DOI: 10.1155/2013/658126] [Cited by in Crossref: 41] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
189 Gao C, Kozlowska A, Nechaev S, Li H, Zhang Q, Hossain DM, Kowolik CM, Chu P, Swiderski P, Diamond DJ, Pal SK, Raubitschek A, Kortylewski M. TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Cancer Res 2013;73:7211-21. [PMID: 24154870 DOI: 10.1158/0008-5472.CAN-13-1314] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
190 Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013;15:R92. [PMID: 24286369 DOI: 10.1186/bcr3493] [Cited by in Crossref: 254] [Cited by in F6Publishing: 271] [Article Influence: 25.4] [Reference Citation Analysis]
191 Formenti SC, Demaria S. Successful clinical translation of preclinical combinations of radiation and immunotherapy. European Journal of Cancer Supplements 2013;11:270. [DOI: 10.1016/j.ejcsup.2013.07.040] [Reference Citation Analysis]
192 Senan S, Paul MA, Lagerwaard FJ. Treatment of early-stage lung cancer detected by screening: surgery or stereotactic ablative radiotherapy? The Lancet Oncology 2013;14:e270-4. [DOI: 10.1016/s1470-2045(12)70592-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 60] [Article Influence: 5.0] [Reference Citation Analysis]
193 Nicholas S, Mathios D, Ruzevick J, Jackson C, Yang I, Lim M. Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors. Brain Tumor Res Treat 2013;1:2-8. [PMID: 24904882 DOI: 10.14791/btrt.2013.1.1.2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
194 Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2012;2:153. [PMID: 23112958 DOI: 10.3389/fonc.2012.00153] [Cited by in Crossref: 162] [Cited by in F6Publishing: 208] [Article Influence: 14.7] [Reference Citation Analysis]
195 Jabbour SK, Berman AT, Simone CB 2nd. Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. Transl Lung Cancer Res 2017;6:113-8. [PMID: 28529894 DOI: 10.21037/tlcr.2017.04.02] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]